by Jakub Jarolím, Business Intelligence Department
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Sotio Biotech
11/4/2022
March 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
NBI is down 25 % since September, number of IPOs are down to a trickle
The NBI added 5 % during March, however it is still down 25 % since September. Most of 2021’s biotech IPO class is trading below listing price; some biotechs are now worth no more than their cash. So far this year, IPOs are down to a trickle or being pulled, investors are cautious.
Antibody-Drug Conjugates
Mirvetuximab showed PFS of 10.6 months in high expression FRα recurrent ovarian cancer
News detail
Share on social networks